Back to News
Market Impact: 0.25

ETF Fundamental Report for IWM

IWMNDAQ
Company FundamentalsMarket Technicals & FlowsAnalyst InsightsHealthcare & Biotech
ETF Fundamental Report for IWM

Validea's fundamental report on the iShares Russell 2000 ETF (IWM), classified as a Mid-Cap Value ETF, details its factor exposures, which could be critical for portfolio construction. While IWM holds a moderate Value score of 63 and Momentum score of 51, it exhibits notably low exposure to Quality (7) and Low Volatility (14), suggesting a higher risk profile. The ETF's largest sector allocation is Services, with Biotechnology & Drugs as its dominant industry.

Analysis

The Validea fundamental report on the iShares Russell 2000 ETF (IWM) provides a clear factor profile, identifying it as a Mid-Cap Value instrument. The ETF exhibits a moderate exposure to the Value factor with a score of 63 out of 99 and a neutral stance on Momentum with a score of 51. Critically, the analysis reveals exceptionally low scores for Quality (7) and Low Volatility (14), indicating that the underlying portfolio consists of companies with potentially weaker fundamentals, lower profitability, and a greater propensity for price fluctuations. This risk profile is compounded by its largest sector allocation being Services and its top industry exposure in Biotechnology & Drugs, a historically volatile segment. The factor composition suggests IWM is not a defensive holding but rather a vehicle for capturing a specific, higher-risk segment of the market.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

IWM0.00
NDAQ0.00

Key Decisions for Investors

  • Investors should recognize that IWM's low Quality score of 7 and Low Volatility score of 14 imply a higher-risk profile, making it more suitable for tactical allocations in a risk-on environment rather than as a core, conservative holding.
  • Given the significant exposure to the Biotechnology & Drugs industry, portfolio managers must closely monitor sector-specific catalysts and risks, as these will have a disproportionate impact on the ETF's performance.
  • Due to its weak quality and high-volatility characteristics, consider balancing an IWM position with investments in higher-quality or minimum-volatility factor ETFs to mitigate portfolio risk, especially during periods of market stress.